

# Linking Patients to Protocols: An Automated Registry Communication System

### Rachel Richesson, PhD, MPH University of South Florida College of Medicine

4th International Conference on Rare Diseases and Orphan Drugs Washington DC, May 20-22, 2008



### Where do I need to go

Welcome! You have reached the home page for the Rare Diseases Clinical Research Network (RDCRN). Each Consortium within the network provides detailed information on several rare diseases.

#### What if I am unsure of which consortium to visit?

Scan the list to the right for a disease name. Once you have located it, click on the link for a brief description which will lead you to the correct consortium.

#### How will this consortium be useful to me?

You can take action! Once you have reached the correct consortium, you will be able to **join the contact registry** for clinical research trials. You will also find several helpful resources that include participating clinical center information, support and advocacy group information and other useful links



#### Clinical Research Consortia :

#### Urea Cycle Disorders Consortium [Study Information]

N-Acetylglutamate Synthase (NAGS) Deficiency Carbamyl Phosphate Synthetase (CPS) Deficiency Ornithine Transcarbamylase (OTC) Deficiency Argininosuccinate Synthetase Deficiency (Citrullinemia I) Citrin Deficiency (Citrullinemia II) Argininosuccinate Lyase Deficiency (Argininosuccinic Aciduria) Arginase Deficiency (Hyperargininemia) Ornithine Translocase Deficiency (HHH) Syndrome

#### Angelman, Rett, and Prader-Willi Syndromes Consortium [Study Information]

Angelman Syndrome Rett Syndrome Prader-Willi Syndrome

#### <u>CINCH - Consortium for Clinical Investigation of</u> Neurological Channelopathies [Study Information]

#### RDCRN Consortium Studies are opening! Learn More >> Last Updated: 11 May 2008

Look here for information on open studies and future studies

#### <u>Vasculitis Clinical Research Consortium [Study</u> Information]


Wegener's Granulomatosis (WG) Microscopic Polyangiitis (MPA) Churg-Strauss Syndrome (CSS) Polyarteritis Nodosa (PAN) Takayasu's Arteritis (TAK) Giant Cell (Temporal) Arteritis (GCA)

#### Rare Genetic Steroid Disorders Consortium [Study Information]

Congenital Adrenal Hyperplasia Androgen Receptor Defects Apparent Mineralocorticoid Excess (Low Renin Hypertension)

#### Rare Thrombotic Diseases Consortium [Study Information]

Antiphospholipid Antibody Syndromes (APS) Heparin-induced Thrombocytopenia (HIT)



### Consortium Website


• The consortium-specific public website provides the public with detailed information about the consortium and how to join the contact registry.






### Consortium Registry Links


• The public consortium website contains a "join the registry" page that provides links to the registry for each disorder.





### **Registry Description**

Description and Purpose of the Rare Diseases Clinical Research Network (RDCRN)					
Contact Registry					
Thank you for your interest in this contact registry. The purpose of this contact registry is to provide an opportunity for individuals with a specific rare disease or disorder to register themselves to receive information about studies conducted by the Rare Diseases Clinical Research Network. You may also learn about progress being made towards treatment advances by researchers who specialize in your disease or disorder.					
By joining the Contact Registry, you will be asked to provide information about you (or your child) and how you can be contacted. The registry will use that information to contact individuals who might qualify for participation in a research study. We may also use your contact information in order to communicate treatment information and sources.					
Because of their rarity, researchers often have difficulty finding enough patients to study these diseases in order to understand and cure them.					
To learn more about the Contact Registry and how it functions, click "Learn More".					
To join the contact registry, click "Join Contact Registry" and give authorization and Join Contact Registry complete the contact registry form.					
If you are currently a member of the Contact Registry and would like to discontinue Update Info enrollment or update your contact information, click "Update Info".					
Close Window					



### Learn More

• A "learn more" page has in depth material pertaining to the contact registry.





### Authorization Agreement

• Registrants must agree to the HIPAA compliant authorization in order to register with the contact registry.

Authorization Agreement RDCRN Contact Registry Please read the following carefully. The submission of information in the registry will be considered your consent to the following statements. Authorization Statement for Use and Disclosure of Protected Health Information The University of South Florida and the Rare Diseases Clinical Research Network Data and Technology Coordinating Center understand that information about you/(your minor child) and your/(your minor child's) health is personal, and we are committed to protecting the privacy of that information. You are granting your authorization before we use your/ (your minor child's) protected health information (PHI) for the purpose of providing you notification of the availability of clinical studies or trials and updates on the results of clinical studies and trials performed within the Rare Diseases Clinical Research Network. This form memorializes your authorization for us to use your PHI for this purpose and helps us make sure that you are properly informed of how this information will be used and/or disclosed. By agreeing to this document you are permitting the Data and Technology Coordinating Center (DTCC) to use PHI collected about you/(your minor child) so that they may contact you with information about availability of clinical studies or trials and provide updates on the results of clinical studies and trials performed by the Rare Diseases Clinical I HEREBY GIVE permission to the Rare Diseases Clinical Research Network to use the information I provide to the online patient registry. I understand that if I enter my or my child's contact information, I agree to be contacted about future research studies. I understand that if I do provide my or my child's name or other contact information, neither will be identified by name or any traceable identification in any report published or distributed without my permission. By clicking the "I Agree" button you are agreeing to the terms and conditions of the statements above. If you consent to the statements above please click "I Agree". Close Window I Agree



### **Registry Form**

• The registration form contains information such as disorder, date of diagnosis, etc.

• The registrant enters their information into the web based form and registers with the Contact Registry.


	legistry Form
Patient Information (Person with disorde	* Field required to Registe
Padent Information (Person with disorde	0
Disorder:	
Wegener's Granulomatosis (WG)	M
Date of Diagnosis (if you don't know the entire date,	please enter as much as possible)
05 JAN 🗹 2008 *	
Day (DD) Month (MMM) Year (YYYY)	
Date of Birth (if you don't know the entire date, pleas	e enter as much as possible)
04 JUL 🖌 1972 -	
Day (DD) Month (MMM) Year (1111)	
Place of birth:	
County: Dade	
State/Province: Florida	<b>~</b>
Country: United States	×
Gender: *	
⊙ Male ○ Fernale	
Ethnicity:	
Hispanic or Latino   Not Hispanic or Latino	tino
Race (check all that apply) :	
American Indian/Alaska Native	
Asian Black or African American	
Black or African American Native Hawaian/Pacific Islander	
White	
Unknown	
Contact Information (Person to be conta	ted)
Contact Information (Person to be conta First name:	Last name:
-	
Prst name: John*	Last name:
Pist name: John * Maling Address:	Last name:
Prst name: John*	Last name:
Pist name: John * Maling Address:	Last name:
Prst name: John Maling Address: 3650 Spectrum Bird Oty:	Last name:
Prst name: John = Maling Address: 3660 Spectrum Bilvd	Last name: Doe
Pet rame: John + Malng Addres: 3850 Spectrum Bild Oby: Tempa +	State/Province: Florida
Pet rune: John	Last name: Doe
Pet rame: John	Last name: Doe
Pet name: John Malng Addres: 3950 Spectrum Bild Oby: Tampa - Country: United States Primary Prome: 813-396-9515 -	State/Province: Fiorda W ZepPosial Code: 3/3612 Becondary Phone:
Pet name: John + Malng Address: 3850 Spectrum BHd Chy: Tempa + Contro: Tempa + Contro: Status + Primary Phong: 813-366-0515 + (co., IPHS-122)	State Inne: Dee * State Province: Fibrida * ZapiProtal Code: 33612 * Geordary Phone: (eq. 19456-1212)
Pet name: John Malng Address: 3950 Spectrum Blvd Otry: Tampe Contry: United States Primar Phone: (8) 396:0515 (4) (4) (4) (5)	State/Province: Fiorda W ZepPosial Code: 3/3612 Becondary Phone:
Pet name: John + Malng Address: 3850 Spectrum BHd Chy: Tempa + Contro: Tempa + Contro: Status + Primary Phong: 813-366-0515 + (co., IPHS-122)	Lat name: Doe
Pet name: John Malng Address: 3950 Spectrum Blvd Otry: Tampe Contry: United States Primar Phone: (8) 396:0515 (4) (4) (4) (5)	State Inne: Dee * State Province: Fibrida * ZapiProtal Code: 33612 * Geordary Phone: (eq. 19456-1212)
Prit name: John	Lat name: Doe
Pet name: John	Let name: Doe
Prit name: John	Let name: Doe
Prot name: John	at name: Dee 
Pet name: John	at name: Dee 
Pet name: John	at name: Dee 
Pet name: John	at name: Dee 
Pet name: John	at name: Dee 
Pet name: John	at name: Dee 
Pet name: John	at name: Dee 
Pet name: John	at name: Dee 



### Registry Acknowledgement Email

• An acknowledge Email is sent to the registrant after they register or if they update their information.


• The registrant is provided with links in the Email to update their information.





### Sample Study Email

- Emails can be sent to registrants by automations, schedules, or manually.
- The Emails can be customized to include content from each Consortium.
- A template is created to improve Email efficiency and quality.





### Sample Study Email

VASCULITIS

UT

Visit us at: www.RareDiseasesNetwork.org/vasculitis	
Dear Kan Young,	Update your c
	information
This is an update from the Vasculitis Clinical Research Consortium. The following study is currently recruiting participants. This update provides information such as a study summary,	we want to keep
eligibility interia, and a list of participating center locations. If you are interested in particip	ing with the latest of
in this study or you have more questions, please contact the center nearest to you.	arformation. Net
ti une statel el periode destrucit, pesse contact de contente de per-	contact informa
Study Name: 5502 - VCRC Longitudinal Protocol for Gant Cell Arteritis	eng enformation, kee contact informa cart he alone spe on the Web:
Study Status: Recruiting	Cold Here to Under
For:	
Gart Cell (Temporal) Artente (GCA)	About the VC
Summary:	The Vaccultie C
In the longitudinal studies, clinical and laboratory information will be collected on patients w	Constraint (vit)
vasculitis to study the disease over an extended period of time. The data from the longitudi	entergradied spice
studies will be used by scientists to study the genetics and causes of vasculitis, find new w	medical centers
to track disease and predict responses, to understand how to treat patients, and much mor	Ingenization.
	research resou
How to Participate:	conducting clin
In order to participate in a study, you must personally contact the study coordinator of any	different farms
the participate in a study, you must personally contact the study operandor of any the participating institutions by phone or by e-mail. Please use the information below to ino	emproving the p
the participating institutions by prone or by e-mail mease use the information below to ing about participation.	The Vacuality constraints (of independent) independent (of independent) conductions independent different forms with vacuality
<ul> <li>Boston University School of Medicine</li> </ul>	The Vession Generalities of p
Boston, Massachusetts	1 Sector Sector
Principal Investoator: Peter Markel, MD Mille	1000
Contact Person: Ashiey Leavitt	and the second second
Office 617-414-2009	Destinates of the Destinates Office Retwork, The V grow and is wo
Office: 617-414-2509 Email: IsovittaBbu edu	Contraction of the
Email: Went apol as	prove and is we new research p condensing visio
	band entiring was back with the v regularty for up
Cleveland Clinic Foundation (VCRC)	and the second second
Cleveland, Ohio	www.Rattingan
Principal Investigator: Carol Langford, MD, MHG	and the second second
Contact Person: Katherine Tuthill	
Office: 215-444-9505	
Email: TUTHELX@ccf.org	
<ul> <li>Julius Hopkins University</li> </ul>	
Battmore, Maryland	
Principal Investigator: Philip Sec. MD, MHS	
Contact Person: Cymbia bethea	
Office: 450-550-4390	
Enal defreci@fra.du	
Mayo Clinic (VCRC)	
Rochester, Minnesota	
Principal Investigator: Steven Viterberg, MD	
Contact Person: Jane Jaquiti	
Office: 507-294-4502	
Email: Josufh Jonefiniep.edu	
Mount Savai Hospital, Toronto Teronto, Orteuro Canada	
Principal Investigator: Simon Carette, MD	
Contact Person: Sara Sutherland, RN, BScN	
Office: 410-506-0616	
Email: S5utherlandD@ntsha.on.ca	
+ St. Joseph's Hospital, Toronto	
<ul> <li>bit. Josephris Hospitale, Ionantio</li> <li>Hamilton, Ontanio Canada</li> </ul>	
Principal Investigator: Nader Khaldi, MD	
Contact Person: Sandra Messier, RCT	
Office: 905-531-5981	
Email: messier@itjoet.ca	
Airticipation in research studies is voluntary. Deciding not to participate in a research stud	
does not affect your ability to receive care at any of our Clinical Centers or from other.	
physiciane.	100 C
The e-mail has been sent to Ken Young (youngkig@egi.usf.edu) from the Rare Diseases Clinical	elearch Natwork (storge
The second se	and the second second
The Raw Diseases Clinical Research Network (ROOR) was established by	e Natonal Institutes of Heal
contraction of the states for rare diseases, and to encourage cooperative party	rips among researchers at
About the RDCRN clearly around the work! The increased cooperation may lead prevent these rare diseases, as well as produce medical adverses.	CONCEPTION THAT WIT PARE &
	at was perent the populator

Manual Lanter for Annual Sciences Annual Sciences Streets



## Automated Communications

- Typical automations:
  - Welcome
  - New Study
  - New Clinical Site
  - Periodic (every 6 months)
- Automations can be customized by study or consortium

### Administrator Interface: Campaign Manager

RAREDISEASES

\_ - X

NETWORK

🐱 Contact Registry Campaign Manager

#### File View

#### RDCRN

#### Contact Registry Campaign Manager

Campaign List	Campai	gns Registrants	3						
🖃 🧐 Campaigns	New								
⊕ _ 🔁 VCRC Initial				T and	1 martine	1 verse	1 against and	L'and the second second	Contact
⊕ 🛅 UCDC Initial		Campaign	Description	Туре	Status	Date	Consortia	Documents	History
🖶 🛅 BMF Initial	•	VCRC Initial	VCRC Initial	Newsletter	Active	14/Jul/2006	Consortia	Documents	Contact Hist
🖶 🛅 VCRC Pittsburg Seminar		UCDC Initial	UCDC Initial	Newsletter	Active	02/Aug/2006	Consortia	Documents	Contact Hist
⊕– 🫅 UCDC January 2007		BMF Initial	BMF Initial C	Newsletter	Active	24/Aug/2006	Consortia	Documents	Contact Hist
🕀 🛅 GDMCC January 2007	· · · · · · · · · · · · · · · · · · ·	VCRC Pitts	Seminar in Pi		Active	06/Oct/2006	Consortia	Documents	Contact Hist
Automation ARPWS		UCDC Janu	UCDC Janu	Contraction and a set	Active	10/Jan/2007	Consortia	Documents	Contact Hist
😑 🛅 Automation BMF		GDMCC Ja	GDMCC Jan		Active	22/Jan/2007	A Million and a second second	Concernant and the second s	and the second se
Documents		Concernance of the second seco	And the second second second	N. COLORADOR	AVENUS VER	CARGO YOU CHOOLES HOW	Consortia	Documents	Contact Hist
E Consortia	· · · · · · · · · · · · · · · · · · ·	Automation	Angelman, R.		Active	12/Mar/2007	<u>Consortia</u>	Documents	Contact Hist
🕀 👼 Search Criteria		Automation	BMF Consort	Contraction and Area	Active	12/Mar/2007	<u>Consortia</u>	Documents	Contact Hist
⊕ 🗔 Automations	· · · · · · · · · · · · · · · · · · ·	Automation	Cholestatic L.		Active	12/Mar/2007	<u>Consortia</u>	Documents	Contact Hist
Automation CLIC     Automation GDMCC		Automation	GDMCC Aut	Newsletter	Active	12/Mar/2007	<u>Consortia</u>	<u>Documents</u>	Contact Hist
		Automation	Automation	Newsletter	Active	12/Mar/2007	<u>Consortia</u>	<b>Documents</b>	Contact Hist
		Automation	Automation	Newsletter	Active	12/Mar/2007	Consortia	Documents	Contact Hist
		Automation	Automation	Newsletter	Active	12/Mar/2007	Consortia	Documents	Contact Hist
⊕ automation RTDCRC		Automation	Automation	Newsletter	Active	12/Mar/2007	Consortia	Documents	Contact Hist
		A. 4	Automation	Manualattaa	Astice	12/14 /2007	Connection	Desuments	Contrast Ultra
Documents     Consortia     Consortia     Automations     Scheduled Email Update UCDC [ACTIVE]     Automation VCRC     Documents     Consortia     Search Crteria     Automations     S502 Protocol Activation Update [ACTIVE]     S503 Protocol Activation Update [ACTIVE]     S504 Protocol Activation Update [ACTIVE]     S505 Protocol Activation Update [ACTIVE]     S505 Protocol Activation Update [ACTIVE]     S506 Protocol Activation Update [ACTIVE]									

## Administrator Interface: Campaign Configuration

C	ACCREDING AND		1.
Campai	gn /	Autom	ation
	9		

20 C		and the second se
	Automation	
Campaign:		BIVIE
Jan pargn.	/ (utorriguorr	

Campaign:	-	Automation BMF
Consortium:		Bone Marrow Failure Disease Consortium
Protocol:		
Document:	•	Merged Study Update - BMF (Email)
Teleform Document:		
Automation Description:	•	Scheduled Email Upate BMF
Action:	•	Scheduled Email
Active:		
Campaign Search Criteria:	•	BMF AII
Execution Date:		12/Mar/2007
Use Execution Date:		
Recurrence:		
		Recurrence Pattern
		Recur every 6 month(s)
		Recurrence Range
		Start: 30/ Apr /2007 💌 💿 No end date
		O End by: 01/Aug/2007 ♥
		Save

RARE

- 🗆 🗙

### Administrator Interface: Registrant Information and Updates



🐱 Contact Registry Campaign Manager						_ 7 ×
File View						
RDCRN						
Contact Registry Campaign Manager						
Campaign List	Campaigns Registrants					
🖶 🛅 BMF Initial	Consortium:	-Select-				1
VCRC Pittsburg Seminar	Consortium:	-Select-	*			
UCDC January 2007	Disease:		-			
GDMCC January 2007						
Automation ARPWS	Contact Name:					
🖨 🛅 Automation BMF						
🖨 🛅 Documents	Contact Email Address:			Missing Email Addre	ess	
BMF Blank Template						
Merged Study Update - BMF (Email)	Contact Method:	Email				
Protocol Activation Documenet	Contact State:	Alabama	-			
🖶 🏫 Consortia 🖶 👼 Search Criteria	Contact State.	Alabama		Miles:	From ZipCode:	
	User Id:					
5401 Protocol Update		1 <del></del>				
5403 Protocol Update	Failed to Contact:					
5405 Protocol Update	Campaign (Contact History):		~	Not Contacted		
5406 Protocol Update [ACTIVE]	Campaign (Contact History).		( recent			
Scheduled Email Upate BMF [ACTIVE]	Date From (Contact History):					
Automation CLIC	bate from (contact findoly).					
Automation GDMCC	Date To (Contact History):					
Automation GSDC	Display Withdrawn:					
Automation CINCH						
Automation RLDC	Search Sa	ve Search Load Saved Search	Clear Search			
Automation RTDCRC     Automation UCDC		1	Contact	))	7	0
	Select Contact N	ame Disease Consortium	Method Addres	ss Email 🔺	Phone	UserId/Key
Urea Cycle Disorders Consortium						
😑 🕎 Search Criteria						
🖃 🌄 Automations						
Scheduled Email Update UCDC [ACTIVE]						
- Data Automation VCRC						
Documents						
Merged Study Update - VCRC (Email)						
VCRC Blank Template						
VCRC Protocol Update Email						
<ul> <li>A Consortia</li> <li>A Vasculitis Clinical Research Consortium</li> </ul>						
Search Criteria	Select All					
Automations						
5502 Protocol Activation Update [ACTIVE]	Contact Selected Registrant	S				
5503 Protocol Activation Update [ACTIVE]						
5504 Protocol Activation Update [ACTIVE]	<					>
Logged On User: Kenny Young	31					

## Enrollment



Consortia	Ν
Angelman, Rett, & Prader-Willi Syndromes	715
Bone Marrow Failure Disease	356
Cholestatic Liver Disease	263
Neurologic Channelopathies	134
Genetic Diseases of Mucociliary Clearance	251
Genetic Steroid Disorders	46
Rare Lung Disease	247
Rare Thrombotic Disease	384
Urea Cycle Disorders	<mark>25</mark> 4
Vasculitis	1710
Total	<b>4360</b>




## Preferred Contact Method

Contact Method	Ν	Percent
Email	3106	71%
Fax	10	0%
Mail	558	13%
Missing	41	1%
Phone	645	15%
RA	4360	100%



## Reported Referral Method

How did you find out about us?	N	Percent
Internet	1896	43%
Media	6	0%
Medical Professional	365	8%
Missing	24	1%
Other	99	2%
Publication	141	3%
Support Group or Foundation	1742	40%
Word of mouth	87	2%
KAKEI	4360	100%




RARE

ETWORK

Month







## Contact Registry's Global Reach



•10-15% of the Contact Registry have non-US, non-Canada Addresses

•Over 60 countries represented



## Enrollment on Clinical Studies

		Within 200 miles of a clinical site	Within 100 miles of a clinical site
Clinical Research Consortium	Total # of Contact Registrants Eligible for Studies (% enrolled in selected studies)	Total # of Contact Registrants Eligible for Studies (% enrolled in selected studies)	Total # of Contact Registrants Eligible for Studies (% enrolled in selected studies)
Angelman, Rett, & Prader-Willi	648 (15%)	213 (20%)	98 (29%)
Bone Marrow Failures	282 (7%)	96 (13%)	46 (17%)
Genetic Diseases of Mucociliary Clearance	315 (27%)	52 (42%)	32 (28%)
Urea Cycle Disorders	207 (27%)	97 ( <mark>37%)</mark>	68 (43%)
Vasculitis	1325 (6%)	482 (8%)	<mark>229 (12%</mark> )
All sampled studies (12, 2/23/2006)	2777 (12%)	940 (16%)	473 (21%)




## Summary

- Data-driven and automated system
- Fast
- Customizable
- Flexible
- Scalable
- Effective



## **Future Directions**

- Additional diseases
- Link to Clinical Trial Registries to expand the database of available studies
- Ability to download information sheets to discuss with own physician



## Acknowledgements

- NIH Office of Rare Diseases (ORD)
- NIH National Center for Research Resources (NCRR)
- RDCRN Coalition of Patient Advocacy Groups (CPAG)
- Ken Young
- Jennifer Lloyd

Supported by Grant # RR019259 from the NCRR, an NIH component, and the Office of Rare Diseases. Contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or ORD or NIH.



## Questions

## Jeffrey Krischer, PhD Jeffrey.Krischer@epi.usf.edu

Rachel Richesson, PhD, MPH Rachel.Richesson@epi.usf.edu